Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022

Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 season

Published:2024-04 Issue: Volume:224 Page:105853
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Goto Takeyuki^ORCID,Kawai Naoki,Bando Takuma,Takasaki Yoshio,Shindo Shizuo,Tani Naoki,Chong Yong,Ikematsu Hideyuki^ORCID

Funder

Shionogi

Publisher

Elsevier BV

Reference23 articles.

1. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: a Japanese multicenter study in the 2019–2020 influenza season;Chong;Antivir. Res.,2021

2. In vitro neuraminidase inhibitory concentrations (IC50) of four neuraminidase inhibitors in the Japanese 2022–23 season: comparison with the 2010–11 to 2019–20 seasons;Goto;J. Infect. Chemother.,2023

3. Baloxavir marboxil for uncomplicated influenza in adults and adolescents;Hayden;N. Engl. J. Med.,2018

4. Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes;Hirotsu;Clin. Infect. Dis.,2020

5. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons;Ikematsu;J. Infect. Chemother.,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022–2023 influenza season in Japan;Antiviral Research;2024-09